The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
HIV Infection and the Risk of Acute Myocardial Infarction
Open accessAbstract
IMPORTANCE: Whether people infected with human immunodeficiency virus (HIV) are at an increased risk of acute myocardial infarction (AMI) compared with uninfected people is not clear. Without demographically and behaviorally similar uninfected comparators and without uniformly measured clinical data on risk factors and fatal and nonfatal AMI events, any potential association between HIV status and AMI may be confounded. OBJECTIVE: To investigate whether HIV is associated with an increased risk of AMI after adjustment for all standard Framingham risk factors among a large cohort of HIV-positive and demographically and behaviorally similar (ie, similar prevalence of smoking, alcohol, and cocaine use) uninfected veterans in care. DESIGN AND SETTING: Participants in the Veterans Aging Cohort Study Virtual Cohort from April 1, 2003, through December 31, 2009. PARTICIPANTS: After eliminating those with baseline cardiovascular disease, we analyzed data on HIV status, age, sex, race/ethnicity, hypertension, diabetes mellitus, dyslipidemia, smoking, hepatitis C infection, body mass index, renal disease, anemia, substance use, CD4 cell count, HIV-1 RNA, antiretroviral therapy, and incidence of AMI. MAIN OUTCOME MEASURE: Acute myocardial infarction. RESULTS: We analyzed data on 82 459 participants. During a median follow-up of 5.9 years, there were 871 AMI events. Across 3 decades of age, the mean (95% CI) AMI events per 1000 person-years was consistently and significantly higher for HIV-positive compared with uninfected veterans: for those aged 40 to 49 years, 2.0 (1.6-2.4) vs 1.5 (1.3-1.7); for those aged 50 to 59 years, 3.9 (3.3-4.5) vs 2.2 (1.9-2.5); and for those aged 60 to 69 years, 5.0 (3.8-6.7) vs 3.3 (2.6-4.2) (P < .05 for all). After adjusting for Framingham risk factors, comorbidities, and substance use, HIV-positive veterans had an increased risk of incident AMI compared with uninfected veterans (hazard ratio, 1.48; 95% CI, 1.27-1.72). An excess risk remained among those achieving an HIV-1 RNA level less than 500 copies/mL compared with uninfected veterans in time-updated analyses (hazard ratio, 1.39; 95% CI, 1.17-1.66). CONCLUSIONS AND RELEVANCE: Infection with HIV is associated with a 50% increased risk of AMI beyond that explained by recognized risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
Kuller, L. H., Tracy, R., Belloso, W., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050203 · Cited by 1,617
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613
Cited by
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
Future challenges for clinical care of an ageing population infected with HIV: a modelling study
Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., Sighem, A. V., de Wolf, F., & Hallett, T. B. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00056-0 · Cited by 908
Systemic Effects of Inflammation on Health during Chronic HIV Infection
Deeks, S. G., Tracy, R., & Douek, D. C. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.001 · Cited by 868
Self-citationHIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“However, the use of statins remains relatively low in HIV-infected patients.(580,672) The low use of statins in the HIV-infected population may reflect the relatively low prevalence of elevated LDL-C, their uncertain efficacy for CVD prevention, and the potential for adverse side effects and negative drug-drug interac…”
BackgroundBekker, L.-G., Alleyne, G., Baral, S., Cepeda, J., Daskalakis, D., Dowdy, D., Dybul, M., Eholie, S., Esom, K., Garnett, G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31070-5 · Cited by 763
Schouten, J., Wit, F. W., Stolte, I. G., Kootstra, N. A., van der Valk, M., Geerlings, S. E., Prins, M., Reiss, P., for the AGEhIV Cohort Study Group, Reiss, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu701 · Cited by 752
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Packer, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Fletcher, C. V., Staskus, K., Wietgrefe, S. W., Rothenberger, M., Reilly, C., Chipman, J. G., Beilman, G. J., Khoruts, A., Thorkelson, A., Schmidt, T. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318249111 · Cited by 664
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., Post, W. S., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 658
Self-citationDeeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Grinspoon, S. K., Fitch, K. V., Zanni, M. V., Fichtenbaum, C. J., Umbleja, T., Aberg, J. A., Overton, E. T., Malvestutto, C. D., Bloomfield, G. S., Currier, J. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304146 · Cited by 502
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Croxford, S., Kitching, A., Desai, S., Kall, M., Edelstein, M., Skingsley, A., Burns, F., Copas, A., Brown, A. E., Sullivan, A. K., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(16)30020-2 · Cited by 400
Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-1-201307020-00645 · Cited by 393
Severino, P., D'Amato, A., Pucci, M., Infusino, F., Adamo, F., Birtolo, L. I., Netti, L., Montefusco, G., Chimenti, C., Lavalle, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218118 · Cited by 349
Residual Immune Dysregulation Syndrome in Treated HIV infection
Lederman, M. M., Funderburg, N. T., Sekaly, R. P., Klatt, N. R., & Hunt, P. W. (2013) · Advances in Immunology · doi:10.1016/b978-0-12-407707-2.00002-3 · Cited by 348
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy
Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz407 · Cited by 327
Freiberg, M. S., Chang, C.-C. H., Skanderson, M., Patterson, O. V., DuVall, S. L., Brandt, C. A., So-Armah, K. A., Vasan, R. S., Oursler, K. A., Gottdiener, J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0264 · Cited by 313
Self-citationHIV and cardiovascular disease
So-Armah, K., Benjamin, L. A., Bloomfield, G. S., Feinstein, M. J., Hsue, P., Njuguna, B., & Freiberg, M. S. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30036-9 · Cited by 313
Self-citationGross, A. M., Jaeger, P. A., Kreisberg, J. F., Licon, K., Jepsen, K. L., Khosroheidari, M., Morsey, B. M., Swindells, S., Shen, H., Ng, C. T., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.019 · Cited by 306
Williams, E. C., Hahn, J. A., Saitz, R., Bryant, K., Lira, M. C., & Samet, J. H. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13204 · Cited by 294
Self-citationWing, E. J. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.004 · Cited by 287
Althoff, K. N., McGinnis, K. A., Wyatt, C. M., Freiberg, M. S., Gilbert, C., Oursler, K. K., Rimland, D., Rodriguez-Barradas, M. C., Dubrow, R., Park, L. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu869 · Cited by 276
Self-citationBourgi, K., Jenkins, C. A., Rebeiro, P. F., Shepherd, B. E., Palella, F., Moore, R. D., Althoff, K. N., Gill, J., Rabkin, C. S., Gange, S. J., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25484 · Cited by 246
Self-citation2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Hernandez-Romieu, A. C., Garg, S., Rosenberg, E. S., Thompson-Paul, A. M., & Skarbinski, J. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000304 · Cited by 213
Obesity and weight gain in persons with HIV
Bailin, S. S., Gabriel, C. L., Wanjalla, C. N., & Koethe, J. R. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00483-5 · Cited by 213
Diagnosing and managing diabetes in HIV-infected patients: current concepts
Monroe, A. K., Glesby, M. J., & Brown, T. T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu779 · Cited by 125
“HIV-uninfected controls [6, 70], likely caused a combination of factors including metabolic derangement, lifestyle factors such as smoking, and chronic inflammation.”
BackgroundWriting Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Metabolic syndrome, diabetes, and cardiovascular risk in HIV
Nix, L. M., & Tien, P. C. (2014) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0219-7 · Cited by 96
Losina, E., Hyle, E. P., Borre, E. D., Linas, B. P., Sax, P. E., Weinstein, M. C., Rusu, C., Ciaranello, A. L., Walensky, R. P., & Freedberg, K. A. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix547 · Cited by 62
Evidence-based review of statin use in patients with HIV on antiretroviral therapy
Chastain, D. B., Stover, K. R., & Riche, D. M. (2017) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2017.01.004 · Cited by 54
Cardiovascular disease risk in an aging HIV population: not just a question of biology
So-Armah, K., & Freiberg, M. S. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000065 · Cited by 45
Self-citationChichetto, N. E., Kundu, S., Freiberg, M. S., Koethe, J. R., Butt, A. A., Crystal, S., So-Armah, K. A., Cook, R. L., Braithwaite, R. S., Justice, A. C., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03327-4 · Cited by 20
Self-citationContribution of behavioral health factors to non-AIDS-related comorbidities: an updated review
Chichetto, N. E., Polanka, B. M., So-Armah, K. A., Sung, M., Stewart, J. C., Koethe, J. R., Edelman, E. J., Tindle, H. A., & Freiberg, M. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00498-y · Cited by 17
Self-citationChen, Y.-F., Hebert, V. Y., Stadler, K., Xue, S. Y., Slaybaugh, K., Luttrell-Williams, E., Glover, M. C., Krzywanski, D. M., & Dugas, T. R. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09520-1 · Cited by 10
Metadata
- Authors
- Freiberg, M. S., Chang, C.-C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., Butt, A. A., Bidwell Goetz, M., Leaf, D., Oursler, K. A., Rimland, D., Rodriguez Barradas, M., Brown, S., Gibert, C., McGinnis, K., Crothers, K., Sico, J., Crane, H., Warner, A., Gottlieb, S., Gottdiener, J., Tracy, R. P., Budoff, M., Watson, C., Armah, K. A., Doebler, D., Bryant, K., & Justice, A. C.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2013-04-22
- Volume
- 173
- Issue
- 8
- Pages
- 614
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2162249283
- Cited by
- 1,340
- References
- 40
- FWCI
- 106.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.